Skip to main content
Top
Published in: BMC Infectious Diseases 1/2009

Open Access 01-12-2009 | Research article

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

Authors: Claudia Alteri, Valentina Svicher, Caterina Gori, Roberta D'Arrigo, Massimo Ciccozzi, Francesca Ceccherini-Silberstein, Marina Selleri, Stefano Aviani Bardacci, Massimo Giuliani, Paola Elia, Paola Scognamiglio, Roberta Balzano, Nicoletta Orchi, Enrico Girardi, Carlo Federico Perno, SENDIH Study Group

Published in: BMC Infectious Diseases | Issue 1/2009

Login to get access

Abstract

Background

The transmission of HIV-1 drug-resistant strains in drug naive patients may seriously compromise the efficacy of a first-line antiretroviral treatment. To better define this problem, a study in a cohort of newly diagnosed HIV-1 infected individuals has been conducted. This study is aimed to assess the prevalence and the patterns of the mutations recently associated with transmitted drug resistance in the reverse transcriptase (RT) and in protease (PR) of HIV-1.

Methods

Prevalence of transmitted drug resistant strains is determined in 255 newly diagnosed HIV-1 infected patients enrolled in different counselling and testing (CT) centres in Central Italy; the Avidity Index (AI) on the first available serum sample is also used to estimate time since infection. Logistic regression models are used to determine factors associated with infection by drug resistant HIV-1 strains.

Results

The prevalence of HIV-1 strains with at least one major drug resistance mutation is 5.9% (15/255); moreover, 3.9% (10/255) of patients is infected with HIV nucleoside reverse transcriptase inhibitor (NRTI)-resistant viruses, 3.5% (9/255) with HIV non-NRTI-resistant viruses and 0.4% (1/255) with HIV protease inhibitor (PI)-resistant viruses. Most importantly, almost half (60.0%) of patients carries HIV-1 resistant strains with more than one major drug resistance mutation. In addition, patients who had acquired HIV through homosexual intercourses are more likely to harbour a virus with at least one primary resistance mutation (OR 7.7; 95% CI: 1.7–35.0, P = 0.008).

Conclusion

The prevalence of drug resistant HIV-1 strains among newly diagnosed individuals in Central Italy is consistent with the data from other European countries. Nevertheless, the presence of drug-resistance HIV-1 mutations in complex patterns highlights an additional potential risk for public health and strongly supports the extension of wide genotyping to newly diagnosed HIV-1 infected patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B, UK Collaborative Group on HIV Drug Resistance: Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005, 192: 967-73. 10.1086/432763.CrossRefPubMed Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B, UK Collaborative Group on HIV Drug Resistance: Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 2005, 192: 967-73. 10.1086/432763.CrossRefPubMed
2.
go back to reference Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A, Collaborative Group for Clinical Use of HIV Genotype Resistance Test: Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther. 2006, 11: 553-560.PubMed Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A, Collaborative Group for Clinical Use of HIV Genotype Resistance Test: Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther. 2006, 11: 553-560.PubMed
3.
go back to reference Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B, Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group: Prevalence of HIV- drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr. 2007, 46: 12-28.PubMed Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B, Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group: Prevalence of HIV- drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr. 2007, 46: 12-28.PubMed
4.
go back to reference Wensing AM, Boucher CA: Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003, 5: 140-155.PubMed Wensing AM, Boucher CA: Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003, 5: 140-155.PubMed
5.
go back to reference Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD: The persistence of transmitted drug resistance among subjects with primary HIV infection. J Virol. 2008, 82: 5510-5528. 10.1128/JVI.02579-07.CrossRefPubMedPubMedCentral Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD: The persistence of transmitted drug resistance among subjects with primary HIV infection. J Virol. 2008, 82: 5510-5528. 10.1128/JVI.02579-07.CrossRefPubMedPubMedCentral
6.
go back to reference Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002, 347: 385-394. 10.1056/NEJMoa013552.CrossRefPubMed Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002, 347: 385-394. 10.1056/NEJMoa013552.CrossRefPubMed
7.
go back to reference Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L, French PRIMO Cohort Study Group (ANRS CO 06); French ANRS AC11 Resistance Study Group: Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther. 2007, 12: 1305-1310.PubMed Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L, French PRIMO Cohort Study Group (ANRS CO 06); French ANRS AC11 Resistance Study Group: Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther. 2007, 12: 1305-1310.PubMed
8.
go back to reference Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B, ANRS CO3 Aquitaine Cohort: Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008, 22: 1417-1423. 10.1097/QAD.0b013e3283034953.CrossRefPubMed Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B, ANRS CO3 Aquitaine Cohort: Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008, 22: 1417-1423. 10.1097/QAD.0b013e3283034953.CrossRefPubMed
9.
go back to reference Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008, 47: 266-285. 10.1086/589297.CrossRefPubMed Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008, 47: 266-285. 10.1086/589297.CrossRefPubMed
11.
go back to reference Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, Berg-Wolf van den M, Kozal M, Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team: Prevalence of antiretroviral drug-resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005, 40: 468-474. 10.1086/427212.CrossRefPubMed Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, Berg-Wolf van den M, Kozal M, Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team: Prevalence of antiretroviral drug-resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005, 40: 468-474. 10.1086/427212.CrossRefPubMed
12.
go back to reference Wensing AM, Vijver van de DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, SPREAD Programme: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005, 192: 958-966. 10.1086/432916.CrossRefPubMed Wensing AM, Vijver van de DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, SPREAD Programme: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005, 192: 958-966. 10.1086/432916.CrossRefPubMed
13.
go back to reference Yerly S, von Wyl V, Ledergerber B, Böni J, Schüpbach J, Bürgisser P, Klimkait T, Rickenbach M, Kaiser L, Günthard HF, Perrin L, Swiss HIV Cohort Study: Transmission of HIV-1 drug-resistance in Switzerland: a 10-year molecular epidemiology survey. Antivir Ther. 2007, 21: 2223-2229. Yerly S, von Wyl V, Ledergerber B, Böni J, Schüpbach J, Bürgisser P, Klimkait T, Rickenbach M, Kaiser L, Günthard HF, Perrin L, Swiss HIV Cohort Study: Transmission of HIV-1 drug-resistance in Switzerland: a 10-year molecular epidemiology survey. Antivir Ther. 2007, 21: 2223-2229.
14.
go back to reference UK Collaborative Group on HIV Drug-resistance, UK Collaborative HIV Cohort Study, UKRegister of HIV Seroconverters: Evidence of a decline in transmitted HIV-1 drug-resistance in the United Kingdom. AIDS. 2007, 21: 1035-1039.CrossRef UK Collaborative Group on HIV Drug-resistance, UK Collaborative HIV Cohort Study, UKRegister of HIV Seroconverters: Evidence of a decline in transmitted HIV-1 drug-resistance in the United Kingdom. AIDS. 2007, 21: 1035-1039.CrossRef
15.
go back to reference Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar JA, Basta MS, Elston JW, Schmid ML, Thaker H, Chadwick DR: Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother. 2008, 62: 464-468. 10.1093/jac/dkn228.CrossRefPubMed Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar JA, Basta MS, Elston JW, Schmid ML, Thaker H, Chadwick DR: Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother. 2008, 62: 464-468. 10.1093/jac/dkn228.CrossRefPubMed
16.
go back to reference SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008, 22: 625-635. 10.1097/QAD.0b013e3282f5e062.CrossRef SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008, 22: 625-635. 10.1097/QAD.0b013e3282f5e062.CrossRef
17.
go back to reference Orchi N, Balzano R, Scognamiglio P, Navarra A, De Carli G, Elia P, Grisetti S, Sampaolesi A, Giuliani M, De Filippis A, Puro V, Ippolito G, Girardi E, SENDIH group: Ageing with HIV: newly diagnosed older adults in Italy. AIDS Care. 2008, 20: 419-425. 10.1080/09540120701867073.CrossRefPubMed Orchi N, Balzano R, Scognamiglio P, Navarra A, De Carli G, Elia P, Grisetti S, Sampaolesi A, Giuliani M, De Filippis A, Puro V, Ippolito G, Girardi E, SENDIH group: Ageing with HIV: newly diagnosed older adults in Italy. AIDS Care. 2008, 20: 419-425. 10.1080/09540120701867073.CrossRefPubMed
18.
go back to reference Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G: Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 2003, 32: 424-428. 10.1097/00126334-200304010-00012.CrossRefPubMed Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G: Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 2003, 32: 424-428. 10.1097/00126334-200304010-00012.CrossRefPubMed
19.
go back to reference Selleri M, Orchi N, Zaniratti MS, Bellagamba R, Corpolongo A, Angeletti C, Ippolito G, Capobianchi MR, Girardi E: Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr. 2007, 46: 145-150. 10.1097/QAI.0b013e318120039b.CrossRefPubMed Selleri M, Orchi N, Zaniratti MS, Bellagamba R, Corpolongo A, Angeletti C, Ippolito G, Capobianchi MR, Girardi E: Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr. 2007, 46: 145-150. 10.1097/QAI.0b013e318120039b.CrossRefPubMed
20.
go back to reference Suligoi B, Buttò S, Galli C, Bernasconi D, Salata RA, Tavoschi L, Chiappi M, Mugyenyi P, Pimpinelli F, Kityo C, Regine V, Rezza G: Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol. 2008, 41: 288-92. 10.1016/j.jcv.2007.11.020.CrossRefPubMed Suligoi B, Buttò S, Galli C, Bernasconi D, Salata RA, Tavoschi L, Chiappi M, Mugyenyi P, Pimpinelli F, Kityo C, Regine V, Rezza G: Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol. 2008, 41: 288-92. 10.1016/j.jcv.2007.11.020.CrossRefPubMed
21.
go back to reference Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF: Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure. AIDS. 2004, 18: 11-19. 10.1097/01.aids.0000131394.76221.02.CrossRef Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF: Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure. AIDS. 2004, 18: 11-19. 10.1097/01.aids.0000131394.76221.02.CrossRef
22.
go back to reference Thompson JD, Higgins DG, Gibson TJ: Clustal W: Improving sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res. 1994, 22: 4673-4680. 10.1093/nar/22.22.4673.CrossRefPubMedPubMedCentral Thompson JD, Higgins DG, Gibson TJ: Clustal W: Improving sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res. 1994, 22: 4673-4680. 10.1093/nar/22.22.4673.CrossRefPubMedPubMedCentral
23.
go back to reference Hall TA: Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser. 1999, 41: 95-98. Hall TA: Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser. 1999, 41: 95-98.
24.
go back to reference de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, Vijver van de DA, Boucher CA, Camacho R, Vandamme AM: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005, 21 (19): 3797-800. 10.1093/bioinformatics/bti607.CrossRefPubMed de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, Vijver van de DA, Boucher CA, Camacho R, Vandamme AM: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005, 21 (19): 3797-800. 10.1093/bioinformatics/bti607.CrossRefPubMed
25.
go back to reference Swafford KL: PAUP 4,0: Phylogenetic analysis with parsimony (and other methods), version 4,0b2a. 1999, Sinauer Associates Inc., Sunderland, MA Swafford KL: PAUP 4,0: Phylogenetic analysis with parsimony (and other methods), version 4,0b2a. 1999, Sinauer Associates Inc., Sunderland, MA
26.
go back to reference Posada D, Crandall KA: MODEL TEST: Testing the model of DNA substitution. Bioinformatics. 1998, 14: 817-818. 10.1093/bioinformatics/14.9.817.CrossRefPubMed Posada D, Crandall KA: MODEL TEST: Testing the model of DNA substitution. Bioinformatics. 1998, 14: 817-818. 10.1093/bioinformatics/14.9.817.CrossRefPubMed
27.
go back to reference Ray S: Simplot v3.2 beta. 2002, Baltimore, MD, distributed by author Ray S: Simplot v3.2 beta. 2002, Baltimore, MD, distributed by author
28.
go back to reference Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D: HIV-1 protease and reverse transcriptase mutations for drug-resistance surveillance. AIDS. 2007, 21: 215-223. 10.1097/QAD.0b013e328011e691.CrossRefPubMedPubMedCentral Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D: HIV-1 protease and reverse transcriptase mutations for drug-resistance surveillance. AIDS. 2007, 21: 215-223. 10.1097/QAD.0b013e328011e691.CrossRefPubMedPubMedCentral
29.
go back to reference Shafer RW, Rhee SY, Bennett DE: Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008, 13: 59-68.PubMedPubMedCentral Shafer RW, Rhee SY, Bennett DE: Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008, 13: 59-68.PubMedPubMedCentral
30.
go back to reference Lindström A, Ohlis A, Huigen M, Nijhuis M, Berglund T, Bratt G, Sandström E, Albert J: HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther. 2006, 11: 1031-1039.PubMed Lindström A, Ohlis A, Huigen M, Nijhuis M, Berglund T, Bratt G, Sandström E, Albert J: HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther. 2006, 11: 1031-1039.PubMed
31.
go back to reference Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF: Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Vir. 2006, 80: 7186-7198. 10.1128/JVI.02084-05.CrossRef Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF: Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Vir. 2006, 80: 7186-7198. 10.1128/JVI.02084-05.CrossRef
32.
go back to reference Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicr Agents Chemother. 2000, 44: 2475-8244. 10.1128/AAC.44.9.2475-2484.2000.CrossRef Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicr Agents Chemother. 2000, 44: 2475-8244. 10.1128/AAC.44.9.2475-2484.2000.CrossRef
33.
go back to reference Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 2001, 7: 1016-1020. 10.1038/nm0901-1016.CrossRefPubMed Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 2001, 7: 1016-1020. 10.1038/nm0901-1016.CrossRefPubMed
34.
go back to reference Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE: The epidemiology of antiretroviral drug-resistance among drug naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004, 189: 2174-2180. 10.1086/420789.CrossRefPubMed Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE: The epidemiology of antiretroviral drug-resistance among drug naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004, 189: 2174-2180. 10.1086/420789.CrossRefPubMed
35.
go back to reference Vingerhoets J, Buelens A, Peeters M, Picchio G, Tambuyzer L, Cao Van K, De Smedt G, Woodfall B, de Bethune MP: Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007, 12 (suppl): S34- Vingerhoets J, Buelens A, Peeters M, Picchio G, Tambuyzer L, Cao Van K, De Smedt G, Woodfall B, de Bethune MP: Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007, 12 (suppl): S34-
36.
go back to reference de Ronde A, van Dooren M, Hoek van Der L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J: Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Vir. 2001, 75: 595-602. 10.1128/JVI.75.2.595-602.2001.CrossRef de Ronde A, van Dooren M, Hoek van Der L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J: Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Vir. 2001, 75: 595-602. 10.1128/JVI.75.2.595-602.2001.CrossRef
37.
go back to reference Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Nat Acad Sc USA. 2001, 98: 13907-13912. 10.1073/pnas.241300698.CrossRef Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Nat Acad Sc USA. 2001, 98: 13907-13912. 10.1073/pnas.241300698.CrossRef
38.
go back to reference Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C: Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 2004, 18: 227-235. 10.1097/00002030-200401230-00012.CrossRefPubMed Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C: Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 2004, 18: 227-235. 10.1097/00002030-200401230-00012.CrossRefPubMed
39.
go back to reference Alteri C, Svicher V, Gori C, D'Arrigo R, Santoro MM, Bellocchi MC, Ceccherini-Silberstein F, Orchi N, Girardi E, Perno CF: Complex patterns of drug-resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains. Presented at 6th European HIV Drug-resistance Workshop. 2008, Abstract 13 Alteri C, Svicher V, Gori C, D'Arrigo R, Santoro MM, Bellocchi MC, Ceccherini-Silberstein F, Orchi N, Girardi E, Perno CF: Complex patterns of drug-resistance mutations in newly-diagnosed HIV-infected patients: implications with the transmission of resistant strains. Presented at 6th European HIV Drug-resistance Workshop. 2008, Abstract 13
40.
go back to reference Santoro MM, Ceccherini-Silberstein F, Narciso P, Mussini C, Zaccarelli M, Borghi V, Boumis E, Tozzi V, Visco-Comandini V, Gori C, Forbici F, d'Arrigo R, Bellocchi MC, Bertoli A, Antinori A, Perno CF: Declining of HIV-1 drug resistance in treatment-failing patients: a potential association with more effective antiretroviral regimens. Presented at 6th European HIV Drug Resistance Workshop. 2008, Abstract 2 Santoro MM, Ceccherini-Silberstein F, Narciso P, Mussini C, Zaccarelli M, Borghi V, Boumis E, Tozzi V, Visco-Comandini V, Gori C, Forbici F, d'Arrigo R, Bellocchi MC, Bertoli A, Antinori A, Perno CF: Declining of HIV-1 drug resistance in treatment-failing patients: a potential association with more effective antiretroviral regimens. Presented at 6th European HIV Drug Resistance Workshop. 2008, Abstract 2
Metadata
Title
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
Authors
Claudia Alteri
Valentina Svicher
Caterina Gori
Roberta D'Arrigo
Massimo Ciccozzi
Francesca Ceccherini-Silberstein
Marina Selleri
Stefano Aviani Bardacci
Massimo Giuliani
Paola Elia
Paola Scognamiglio
Roberta Balzano
Nicoletta Orchi
Enrico Girardi
Carlo Federico Perno
SENDIH Study Group
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2009
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-9-111

Other articles of this Issue 1/2009

BMC Infectious Diseases 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.